This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Kułakowski A, Zatoński W. Cancer in Poland in 1990. In: Zatoński W, Tyczyński J, editos. Warsaw: Pracownia Poligraficzna Centrum Onkologii - Instytutu im. Marii Skłodowskiej-Curie; 1990.KułakowskiAZatońskiWCancer in Poland in 1990InZatońskiWTyczyńskiJeditosWarsawPracownia Poligraficzna Centrum Onkologii - Instytutu im. Marii Skłodowskiej-Curie;1990Search in Google Scholar
Didkowska J, Wojciechowska U, Czaderny K, Olasek P, Ciuba A. Cancer in Poland in 2017. Warsaw: Pracownia Poligraficzna Centrum Onkologii - Instytutu im. Marii Skłodowskiej-Curie; 2017. [cited 2020 Feb 1]. Available at: http://onkologia.org.pl/wp-content/uploads/Nowotwory_2017.pdfDidkowskaJWojciechowskaUCzadernyKOlasekPCiubaACancer in Poland in 2017WarsawPracownia Poligraficzna Centrum Onkologii - Instytutu imMarii Skłodowskiej-Curie; 2017. [cited 2020 Feb 1]. Available athttp://onkologia.org.pl/wp-content/uploads/Nowotwory_2017.pdfSearch in Google Scholar
Park SW, Hwang DS, Song WH, Nam JK, Lee HJ, Chung MK. Conditional biochemical recurrence-free survival after radical prostatectomy in patients with high-risk prostate cancer. Prostate Int 2020; 8: 173-7. doi: 10.1016/j.prnil.2020.07.004ParkSWHwangDSSongWHNamJKLeeHJChungMKConditional biochemical recurrence-free survival after radical prostatectomy in patients with high-risk prostate cancerProstate Int20208173710.1016/j.prnil.2020.07.004Open DOISearch in Google Scholar
Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956-62. doi: 10.1016/j.juro.2008.11.032ThompsonIMTangenCMParadeloJLuciaMSMillerGTroyerDet alAdjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trialJ Urol20091819566210.1016/j.juro.2008.11.032Open DOISearch in Google Scholar
Bolla M, Van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012; 380: 2018-27. doi: 10.1016/S0140-6736(12)61253-7BollaMVanPoppel HTombalBVekemansKDa PozzoLde ReijkeTMet alPostoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)Lancet201238020182710.1016/S0140-6736(12)61253-7Open DOISearch in Google Scholar
Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol 2014; 66: 243-50. doi: 10.1016/j.eururo.2014.03.011WiegelTBartkowiakDBottkeDBronnerCSteinerUSiegmannAet alAdjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trialEur Urol2014662435010.1016/j.eururo.2014.03.011Open DOISearch in Google Scholar
Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol 2016; 34: 3648-54. doi: 10.1200/JCO.2016.67.9647TendulkarRDAgrawalSGaoTEfstathiouJAPisanskyTMMichalskiJMet alContemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomyJ Clin Oncol20163436485410.1200/JCO.2016.67.9647Open DOISearch in Google Scholar
Mottet N, Conford P, van den Bergh RCN, Briers E, De Santis M, Fantis S, et al. Prostate Cancer EAU Guidelines. Presented at the EAU Annual Congress Barcelona 2019. Arnhem, the Netherlands: EAU Guidelines Office; 2019. [cited 2020 Feb 1]. Available at: https://uroweb.org/guideline/prostate-cancer/MottetNConfordPvan denBergh RCNBriersEDe SantisMFantisSet alProstate Cancer EAU Guidelines. Presented at the EAU Annual Congress Barcelona2019Arnhem, the NetherlandsEAU Guidelines Office2019[cited 2020 Feb 1]. Available athttps://uroweb.org/guideline/prostate-cancer/Search in Google Scholar
Kneebone A, Fraser-Browne C, Delprado W, Duchesne G, Fisher R, Frydenberg M, et al. A phase III multi-centre randomised trial comparing adjuvant versus early salvage radiotherapy following a radical prostatectomy: results of the TROG 08.03 and ANZUP “RAVES” trial. Int J Radiat Oncol 2019; 105: S37-8. doi: 10.1016/j.ijrobp.2019.06.456KneeboneAFraser-BrowneCDelpradoWDuchesneGFisherRFrydenbergMet alA phase III multi-centre randomised trial comparing adjuvant versus early salvage radiotherapy following a radical prostatectomy: results of the TROG 08.03 and ANZUP “RAVES” trialInt J Radiat Oncol2019105S37810.1016/j.ijrobp.2019.06.456Open DOISearch in Google Scholar
Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet 2020; 396: 1413-21. doi: 10.1016/S0140-6736(20)31553-1ParkerCCClarkeNWCookADKynastonHGPetersenPMCattonCet alTiming of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trialLancet202039614132110.1016/S0140-6736(20)31553-1Open DOISearch in Google Scholar
Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol 2020; 21: 1341-52. doi: 10.1016/S1470-2045(20)30454-XSargosPChabaudSLatorzeffIMagnéNBenyoucefASupiotSet alAdjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trialLancet Oncol20202113415210.1016/S1470-2045(20)30454-XOpen DOISearch in Google Scholar
Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet 2020; 396: 1422-31. doi: 10.1016/S0140-6736(20)31952-8ValeCLFisherDKneeboneAParkerCPearseMRichaudPet alAdjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate dataLancet202039614223110.1016/S0140-6736(20)31952-8Open DOISearch in Google Scholar
RAVES-Contouring Guidelines Revised July 2011. CTV Delineation. [cited 2020 Aug 15]. Available at: https://www.trog.com.au/SiteFiles/trogcomau/TROG_0803_-_Guidelines_for_Contouring.pdfRAVES-Contouring Guidelines Revised July 2011. CTV Delineation[cited 2020 Aug 15]. Available athttps://www.trog.com.au/SiteFiles/trogcomau/TROG_0803_-_Guidelines_for_Contouring.pdfSearch in Google Scholar
Tourinho-Barbosa R, Srougi V, Nunes-Silva I, Baghdadi M, Rembeyo G, Eiffel SS, et al. Biochemical recurrence after radical prostatectomy: what does it mean? Int Braz J Urol 2018; 44: 14-21. doi: 10.1590/S1677-5538.IBJU.2016.0656Tourinho-BarbosaRSrougiVNunes-SilvaIBaghdadiMRembeyoGEiffelSSet alBiochemical recurrence after radical prostatectomy: what does it mean?Int Braz J Urol201844142110.1590/S1677-5538.IBJU.2016.0656581552829039897Open DOISearch in Google Scholar
Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol 2019; 75: 967-87. doi: 10.1016/j.eururo.2018.10.011Vanden Broeck Tvan denBergh RCNArfiNGrossTMorisLBriersEet alPrognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic reviewEur Urol2019759678710.1016/j.eururo.2018.10.011Open DOISearch in Google Scholar
Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, et al. Metastasisfree survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol 2017; 35: 3097-104. doi: 10.1200/JCO.2017.73.9987XieWReganMMBuyseMHalabiSKantoffPWSartorOet alMetastasisfree survival is a strong surrogate of overall survival in localized prostate cancerJ Clin Oncol201735309710410.1200/JCO.2017.73.9987Open DOISearch in Google Scholar
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 1999; 281: 1591-7. doi: 10.1001/jama.281.17.1591PoundCRPartinAWEisenbergerMAChanDWPearsonJDWalshPCNatural history of progression after PSA elevation following radical prostatectomyJ Am Med Assoc19992811591710.1001/jama.281.17.1591Open DOISearch in Google Scholar
Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, et al. Comparison between adjuvant and early-salvage postprostatectomy radiotherapy for prostate cancer with adverse pathological features. JAMA Oncol 2018; 4: e175230. doi: 10.1001/jamaoncol.2017.5230HwangWLTendulkarRDNiemierkoAAgrawalSStephansKLSprattDEet alComparison between adjuvant and early-salvage postprostatectomy radiotherapy for prostate cancer with adverse pathological featuresJAMA Oncol20184e17523010.1001/jamaoncol.2017.5230Open DOISearch in Google Scholar
Dalela D, Santiago-Jiménez M, Yousefi K, Karnes RJ, Ross AE, Den RB, et al. Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model. J Clin Oncol 2017; 35: 1982-90. doi: 10.1200/JCO.2016.69.9918DalelaDSantiago-JiménezMYousefiKKarnesRJRossAEDenRBet alGenomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic modelJ Clin Oncol20173519829010.1200/JCO.2016.69.9918Open DOISearch in Google Scholar
Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 2020; 21: 1331-40. doi: 10.1016/S1470-2045(20)30456-3KneeboneAFraser-BrowneCDuchesneGMFisherRFrydenbergMHerschtalAet alAdjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trialLancet Oncol20202113314010.1016/S1470-2045(20)30456-3Open DOISearch in Google Scholar
Alipour R, Azad A, Hofman MS. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol 2019; 11: 1758835919876828. doi: 10.1177/1758835919876828AlipourRAzadAHofmanMSGuiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?Ther Adv Med Oncol201911175883591987682810.1177/1758835919876828675564331565073Open DOISearch in Google Scholar
Napieralska A, Miszczyk L, Tukiendorf A, Stąpór-Fudzińska M. The results of treatment of prostate cancer bone metastases after CyberKnife radiosurgery. Ortop Traumatol Rehabil 2014; 16: 339-49. doi: 10.5604/15093492.1112535NapieralskaAMiszczykLTukiendorfAStąpór-FudzińskaMThe results of treatment of prostate cancer bone metastases after CyberKnife radiosurgeryOrtop Traumatol Rehabil2014163394910.5604/15093492.111253525058109Open DOISearch in Google Scholar
Napieralska A, Miszczyk L, Stąpór-Fudzińska M. CyberKnife stereotactic ablative radiotherapy as an option of treatment for patients with prostate cancer having oligometastatic lymph nodes: single-center study outcome evaluation. Technol Cancer Res Treat 2016; 15: 661-73. doi: 10.1177/1533034615595945NapieralskaAMiszczykLStąpór-FudzińskaMCyberKnife stereotactic ablative radiotherapy as an option of treatment for patients with prostate cancer having oligometastatic lymph nodes: single-center study outcome evaluationTechnol Cancer Res Treat2016156617310.1177/153303461559594526208835Open DOISearch in Google Scholar
